Yahoo · Sep 1, 2026
Piper Sandler Lifts Tempus AI to Overweight at $76
Personalis holders receive Tempus shares worth $16.25 each under the pending merger
PS
NASDAQ · PSNL
Personalis, Inc.
Healthcare · Medical - Diagnostics & Research
$16.33
Down-$0.07 (-0.43%)
Updated Sep 11, 2026, 1:24 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 824.5M
- P/E ratio
- -11.15
- Dividend yield
- 0.00%
- 52-week range
- $4.96 – $18.89
- Volume
- 2.3M
- Avg. volume
- 1.34M
Price performance
PSNL price history
1M range · 20 trading sessions · Daily adjusted prices
PSNL closed at $16.33 after 20 trading sessions, up 13.25% for the selected period.
- Last close
- $16.33
- Period change
- +13.25%
- Period low
- $13.89
- Period high
- $18.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $16.07 | $16.49 | $16.00 | $16.33 | 2.3M |
| Sep 9, 2026 | $16.60 | $16.825 | $16.38 | $16.40 | 2.78M |
| Sep 8, 2026 | $17.20 | $17.35 | $16.46 | $16.60 | 2.55M |
| Sep 4, 2026 | $16.67 | $17.23 | $16.52 | $17.20 | 2.52M |
| Sep 3, 2026 | $16.95 | $17.00 | $16.44 | $16.83 | 2.49M |
| Sep 2, 2026 | $17.14 | $17.16 | $16.71 | $16.73 | 2.23M |
| Sep 1, 2026 | $17.00 | $17.3756 | $16.81 | $17.06 | 3.62M |
| Aug 31, 2026 | $17.00 | $17.2438 | $16.60 | $16.78 | 2.85M |
| Aug 28, 2026 | $16.75 | $17.2377 | $16.60 | $17.07 | 2.97M |
| Aug 27, 2026 | $17.08 | $17.64 | $16.55 | $16.80 | 4.94M |
| Aug 26, 2026 | $17.18 | $17.50 | $16.84 | $17.08 | 2.18M |
| Aug 25, 2026 | $17.09 | $17.48 | $16.80 | $17.25 | 2.9M |
| Aug 24, 2026 | $17.01 | $17.43 | $16.79 | $17.06 | 4.79M |
| Aug 21, 2026 | $16.655 | $18.89 | $16.62 | $18.38 | 8M |
| Aug 20, 2026 | $15.91 | $17.0599 | $15.91 | $16.88 | 14.21M |
| Aug 19, 2026 | $15.22 | $15.938 | $14.42 | $15.81 | 8.28M |
| Aug 18, 2026 | $13.77 | $13.98 | $13.68 | $13.91 | 1.03M |
| Aug 17, 2026 | $13.90 | $14.23 | $13.782 | $13.89 | 1.09M |
| Aug 14, 2026 | $14.11 | $14.33 | $13.92 | $14.04 | 1.04M |
| Aug 13, 2026 | $14.295 | $14.51 | $14.03 | $14.42 | 1.17M |
Latest PSNL news
The latest Smart Investors Daily articles mentioning PSNL.
Stock researchCompany · Overview
PSNL research
Overview
Company profile and research snapshot.
Company profile
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.50
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | Needham | Hold | — |
| Jul 20, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | Lake Street | Hold | — |
| Jul 17, 2026 | Needham | Buy | — |
| Jul 9, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
Tempus AI shares rise 2.7% following analyst actions
Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.
Yahoo · Aug 27, 2026
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]
Yahoo · Aug 26, 2026
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.
Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
